Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks8 of 8 passed
Key figures · 17
MetricValuePeriodScopeSource row
Revenue¥1.7bn2024-04-01 → 2024-09-30Cons.Net sales
Operating income−¥263m2024-04-01 → 2024-09-30Cons.Operating income
Ordinary income−¥268m2024-04-01 → 2024-09-30Cons.Ordinary income
Profit before tax−¥241m2024-04-01 → 2024-09-30Cons.Income before income taxes
Net income (owners)−¥242m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income−¥242m2024-04-01 → 2024-09-30Cons.Profit loss
Total assets¥4.6bnat 2024-09-30Cons.Assets
Total liabilities¥3.8bnat 2024-09-30Cons.Liabilities
Net assets / equity¥857mat 2024-09-30Cons.Net assets
Cash and deposits¥1.7bnat 2024-09-30Cons.Cash and deposits
Cash & equivalents¥1.7bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.2bnat 2024-03-31Cons.Cash and cash equivalents
Operating cash flow−¥288m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥3m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥245m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-6.092024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio16.7%at 2024-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 260
ItemContextValueUnit
Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text)CurrentYTDDurationText · Plus
Notes regarding dividend (text)CurrentYTDDurationText · Plus
Notes when there is significant changes in amounts of equity (text)CurrentYTDDurationText · Plus
Notes segment information etc quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Description of fact that companys business comprises single segmentCurrentYTDDuration
Original text (Japanese) 当社は、医薬品開発事業の単一セグメントであるため、記載を省略しております。
Notes revenue recognition quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Notes per share information quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Notes significant events after reporting period quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Other information consolidated financial statements etc (text)CurrentYTDDurationText · Plus
Information about company which provides guarantee to reporting company (text)FilingDateInstantText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 8 of 8 passed
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-09-30pass